TrialInternational clinical psychopharmacology2019

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.

Eduard Vieta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.